Related Experiment Video
Updated: Feb 26, 2026
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with
Phil McEwan1,2, Samantha Webster1, Thomas Ward1
1Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, Cardiff, CF23 8RS UK.
Insights
Daclatasvir plus sofosbuvir (DCV + SOF) is a cost-effective, interferon-free treatment for Hepatitis C virus (HCV) genotype 3. This regimen improves quality of life and reduces costs compared to older treatments.
Area of Science:
- Hepatology
- Pharmacoeconomics
- Virology
Background:
- Hepatitis C virus (HCV) genotype 3 presents unique challenges due to faster disease progression and limited treatment options.
- The shift towards interferon-free direct-acting antiviral (DAA) regimens necessitates evaluating resource allocation for higher-cost treatments.
- Assessing the cost-effectiveness of new DAA regimens is crucial for managing chronic HCV.
Purpose of the Study:
- To estimate the comparative cost-effectiveness of two interferon-free regimens for HCV genotype 3.
- To evaluate daclatasvir + sofosbuvir (DCV + SOF) against sofosbuvir + ribavirin (SOF + RBV) for HCV genotype 3 treatment.
- To inform resource allocation decisions for HCV genotype 3 management in the UK.
Main Methods:
- A published Markov model was utilized for the cost-utility analysis.
- Matching-adjusted indirect comparison of clinical trial data (ALLY-3 and VALENCE) was performed.
- UK-specific cost inputs were applied to compare 12-week DCV + SOF with 24-week SOF + RBV.
Main Results:
- DCV + SOF demonstrated dominance over SOF + RBV in treatment-naïve and previously treated patients.
- DCV + SOF was also found to be cost-effective compared to no treatment in interferon-ineligible/intolerant patients (£8817 ICER).
- The regimen showed favorable outcomes across various patient subgroups.
Conclusions:
- 12 weeks of DCV + SOF offers improved quality of life and reduced total costs compared to 24 weeks of SOF + RBV.
- DCV + SOF represents significant clinical and economic value for treating genotype 3 HCV infection.
- This regimen is a recommended option for managing HCV genotype 3.
Background:
As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3.
Methods:
Utilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12 weeks of treatment with daclatasvir + sofosbuvir (DCV + SOF) was compared to 24 weeks of treatment with sofosbuvir + ribavirin (SOF + RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens.
Results:
In the base case analysis, DCV + SOF was found to be dominant over SOF + RBV in treatment-naïve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV + SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of £8817.
Conclusions:
When compared to 24 weeks of SOF + RBV, 12 weeks of treatment with DCV + SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection.
More Related Videos
13:04A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:09Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...